← 返回

基于国际肺癌研究协会组织学分级与免疫评分的 KRAS 突变浸润性非黏液腺癌预后分类

英文原题:A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma.

查看英文原题

A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma.

PubMed 2022/03/04(内容时间) Thorac Cancer Q2 · IF 2.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

Grading-Immunoscore 分类细化了组织学分级的预后分组,并可能有助于筛选 KRAS 突变腺癌患者中适合免疫治疗的潜在候选者。

中文摘要

肿瘤免疫细胞浸润对肺腺癌患者预后具有重要意义。本研究旨在建立基于肿瘤免疫评分的预后分型。

纳入接受根治性手术的KRAS突变型浸润性非黏液性肺腺癌患者。按照国际肺癌研究协会建议进行组织学分级。采用免疫组化检测程序性死亡配体1(PD-L1)和CD8表达,并评估每个高倍视野内CD8阳性TIL(肿瘤浸润淋巴细胞)数量。依据组织学分级和CD8阳性TIL水平建立“分级-免疫评分”分类:低至中级别且浸润高或低者为A型;高级别、高浸润者为B型;高级别、低浸润者为C型。

共纳入112例患者。多变量分析显示,组织学分级和CD8阳性TIL水平是总生存期(OS)及无进展生存期(PFS)的独立预后因素(P<0.001和P=0.007)。A型患者OS和PFS最佳,C型患者OS最差;三型5年OS分别为89.6%、65.0%和29.5%。B型肿瘤PD-L1阳性率和高表达率最高(肿瘤比例评分[TPS]≥1%:A、B、C型分别为29.4%、73.1%和42.9%;TPS≥50%:分别为7.8%、42.3%和17.1%)。

“分级-免疫评分”分类细化了基于组织学分级的预后分组,并可能有助于筛选KRAS突变腺癌中潜在的免疫治疗候选患者。

展开英文摘要原文

Tumor immune cell infiltration is important in the prognosis of patients with lung adenocarcinoma. The aim of this study was to develop a prognostic classification based on the tumor immunoscore.

Patients with KRAS-mutant invasive non-mucinous lung adenocarcinoma who underwent radical surgery were enrolled in the study. Histologic grading was assessed according to the recommendations of the International Association for the Study of Lung Cancer. Programmed death-ligand 1 (PD-L1) and CD8 expression was detected using immunohistochemistry. The number of CD8 + tumor-infiltrating lymphocytes (TILs) per high-power field was assessed. A classification based on histological grade and CD8 + TIL level was established (Grading-Immunoscore type): low-to-medium grade with high or low infiltration (type A); high-grade, high-infiltration (type B); and high-grade, low-infiltration (type C).

A total of 112 patients participated. In the multivariable analysis, histological grading and level of CD8 + TILs were independent prognostic factors for overall survival (OS) and progression-free survival (PFS) (p < 0.001 and p = 0.007, respectively). Patients with type A tumors had the best OS and PFS, whereas those with type C tumors had the worst OS (89.6%, 65.0%, and 29.5% 5-year OS for types A, B, and C, respectively). PD-L1 positivity and high expression rate was highest in type B tumors (tumor proportion score [TPS] 1%: 29.4%, 73.1%, and 42.9%; TPS 50%: 7.8%, 42.3%, and 17.1%, for types A, B, and C, respectively).

The Grading-Immunoscore classification refines the prognostic grouping of histological grading and might aid in the screening of potential candidates for immunotherapy in patients with KRAS-mutant adenocarcinoma.

论文信息

作者
Chi K、Sun W、Yang X、Wu J、Wang H、Liu X、Mao L、Zhou L
单位
Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.China
文献类型
非美国政府资助研究
期刊
Thoracic cancer2022 Apr
原文标识
PubMed 35246953 · DOI 10.1111/1759-7714.14360